Form D · Biotechnology
Eidos Therapeutics, Inc.
San Francisco, CA · CIK 0001731831
Offering snapshot reported Apr 12, 2018 · SEC filing
- Reported sold
- $26M Offering amount: $74M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 29, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 12, 2018 | Initial | $26,047,857 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-309956
Source: Form D, filed Apr 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Aguiar | Director |
| Jonathan Fox | Executive |
| Hoyoung Huh | Director |
| Neil Kumar | Director, Executive |
| Rajeev Shah | Director |
| Uma Sinha | Executive |
| Christine Siu | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 Montgomery Street, Suite 2550
San Francisco, CA, 94104
San Francisco, CA, 94104